Markets

Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session

Apricus Biosciences, Inc. APRI was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.04-$3.19 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Apricus Biosciences currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Apricus Biosciences, Inc Price and Consensus

Apricus Biosciences, Inc Price and Consensus | Apricus Biosciences, Inc Quote

A better ranked stock in the Medical - Drugs industry is Summit Therapeutics plc SMMT which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is APRI going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Apricus Biosciences, Inc (APRI): Free Stock Analysis Report

Summit Therapeutics PLC (SMMT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SMMT

Other Topics

Investing Stocks

Latest Markets Videos